Showing results (1491-1500 of 1,708) with videos related to

Sort By:
Pageof 171
Lancet (London, England)|September 6, 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trialDeepak L Bhatt, Philippe Gabriel Steg, Shamir R Mehta, et al.
European Journal of Preventive Cardiology|March 23, 2021
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trialRafael Diaz, Qian H Li, Deepak L Bhatt, et al.
Journal of the American Heart Association|August 23, 2021
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 TrialBrian A Bergmark, Deepak L Bhatt, P Gabriel Steg, et al.
Circulation|January 23, 2019
Stroke Outcomes in the COMPASS TrialMukul Sharma, Robert G Hart, Stuart J Connolly, et al.
Circulation|November 12, 2019
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMESJ Wouter Jukema, Laurien E Zijlstra, Deepak L Bhatt, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
Nature Reviews. Cardiology|January 19, 2020
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular diseaseDavide Capodanno, Deepak L Bhatt, John W Eikelboom, et al.
Circulation|October 5, 2020
Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis: The CAMRA CardioLink-2 StudyVincent Chan, C David Mazer, Faeez Mohamad Ali, et al.
Journal of the American College of Cardiology|April 6, 2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery DiseaseMarc P Bonaca, Deepak L Bhatt, Robert F Storey, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 25, 2025
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor TherapyEsther Reijnders, Patrick M Bossuyt, J Wouter Jukema, et al.
Pageof 171